Turkish Validation of the Parkinson Disease Cognitive Functional Rating Scale
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cognition, Parkinson's Disease, Reliability and Validity, Cognitive Functions. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Validity and Reliability Analysis of the Turkish Version of The Parkinson Disease Cognitive Functional Rating Scale
Overview
The aim of the present study is to translate the Parkinson's Disease-Cognitive Functional Rating Scale into Turkish (PD-CFRS-Turkish version) and to evaluate its validity and reliability.
Detailed description
The Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS) is one of the Parkinson's disease-specific instruments developed to assess a broad range of functional impairments resulting from cognitive deficits in individuals with Parkinson's disease (PD). The PD-CFRS is specifically designed to evaluate cognitive dysfunction while minimizing the confounding effects of motor symptoms.
The scale consists of 12 items that assess whether the patient experiences difficulties in performing activities such as managing money and household finances, arranging vacations or meetings, handling personal correspondence, checking medication schedules, organizing daily routines, using electrical appliances, understanding public transportation, dealing with unforeseen situations, expressing intentions, comprehending written information, and using a mobile phone.
Each item is rated on a 3-point scale ranging from 0 to 2. If the participant has never performed the activity in question, a score of 8 is assigned. At the end of the assessment, the average score for items rated between 0 and 2 is calculated and rounded to the nearest whole number. This value replaces all items initially scored as 8. Once all substituted scores are assigned, the total score is obtained by summing all item scores. The administration time for the scale is approximately 5 minutes.
Primary outcome measures
- Validity of the Turkish Version of the Parkinson's Disease Cognitive Functional Rating Scale [Time frame: Baseline]
Secondary outcome measures (6)
- Reliability of the Turkish Version of the Parkinson's Disease Cognitive Functional Rating Scale [Time frame: Repeated measurements will be conducted at a 2 week interval.]
- Mini Mental State Examination Score [Time frame: Baseline]
- Montreal Cognitive Assessment Score [Time frame: Baseline]
- MDS-Unified Parkinson's Disease Rating Scale Part 3: Motor Examination Score [Time frame: Baseline]
- Hoehn and Yahr Scale [Time frame: Baseline]
- Hospital Anxiety and Depression Scale Scores [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Clinically diagnosed with idiopathic Parkinson's disease by a neurologist.
- Evaluated between Stage 1-3 according to the Hoehn and Yahr Staging Scale.
- Aged 40 years or older.
- Agreed to participate in the study after being given sufficient information.
Exclusion criteria
- Patients with a Montreal Cognitive Assessment score of 20 and below.
- Patients with cardiovascular, vestibular, musculoskeletal or additional neurological disease.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Turkey (Türkiye) · 2 centers
- Gazi University, Faculty of Health Sciences — Ankara
- Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital — Ankara
Publications
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. PMID 6880820
- Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003 Aug 1;1:29. doi: 10.1186/1477-7525-1-29. PMID 12914662
- Ozdilek B, Kenangil G. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease. Clin Neuropsychol. 2014;28(2):333-43. doi: 10.1080/13854046.2014.881554. Epub 2014 Feb 17. PMID 24528299
- Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. PMID 15817019
- Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Campolongo A, Garcia-Sanchez C, Pascual-Sedano B, Ribosa-Nogue R, Villa-Bonomo C. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord. 2013 Sep;19(9):812-7. doi: 10.1016/j.parkreldis.2013.05.007. Epub 2013 Jun 15. PMID 23773412
- Kline, P. (1994). An Easy Guide to Factor Analysis (1st ed.). Routledge.
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42. doi: 10.1212/wnl.17.5.427. No abstract available. PMID 6067254
- Aydemir O, Kirpinar I, Sati T, Uykur B, Cengisiz C. Reliability and Validity of the Turkish Version of the Health Anxiety Inventory. Noro Psikiyatr Ars. 2013 Dec;50(4):325-331. doi: 10.4274/npa.y6383. Epub 2013 Dec 1. PMID 28360565
Identifiers
NCT: NCT07253376 · TABED 1-25-1618